The FDA holds its first hearing on CBD in May, as the agency plans to legalize the compound in foods and beverages.
The Food and Drug Administration will hold its first public hearing on the legalization of CBD in food and drink, to determine how to regulate the newly legalized cannabis product. The hearing will take place on May 31.
The agency wants data on the safety of CBD in food products and comments on how it could regulate the manufacturing, marketing and labeling, according to a notice published in Tuesday. the Federal Register.
Scott Gottlieb, outgoing FDA Commissioner, has appointed Amy Abernethy as Senior Assistant Commissioner and Lowell Schiller as Senior Associate Commissioner for Policy. They will co-chair a high-level working group to assess this issue.
“It is essential that we answer these unanswered questions regarding the subject of CBD and other cannabis-derived products to thereby help inform FDA regulatory oversight over these products: particularly as the agency reviews s 'It would be appropriate to allow the use of CBD in dietary supplements and other foods, Gottlieb said in a statement Tuesday.
CBD, short for cannabidiol, is a non-psychoactive compound found in the cannabis plant that promises to relax the body without altering the mind like THC. Congress has legalized the CBD derived from hemp last December.
This situation was believed to result in an increase in the number of consumer products infused with the cannabis compound. However, the FDA's rules banning the addition of CBD in food and drink kept most of the big companies out, though a number of young companies have taken the plunge anyway.
Faced with appeals from Congress, the FDA sought a solution in private. It will now make its efforts public, first with the meeting to be held at its headquarters near Washington, DC Gottlieb said the task force plans to share its findings as early as this summer.
“This is a complicated subject and we expect it to take some time to resolve it completely,” he said. “Nonetheless, we are deeply focused on this issue and we are committed to continuing to engage relevant stakeholders as we consider potential avenues for the future.
The FDA and Federal Trade Commission issued warning letters to three companies on Tuesday: Advanced Spine and Pain's Relievus, Nutra Pure, and PotNetwork Holdings; for allegedly making unproven claims regarding their CBD products, such as helping to treat cancer and Alzheimer's disease.
“The FDA continues to be concerned about the proliferation of blatant medical claims for products claiming to contain CBD that have not been approved by the FDA, such as the products and companies that are receiving letters today. warning, ”Mr. Gottlieb said.
Many other CBD-related companies are making exaggerated health claims and this is the main reason the FDA is making the talk public.